Panosteitis

Panosteitis is a self-limiting, idiopathic, inflammatory bone disease of young, large-breed dogs, characterized by painful, shifting-leg lameness. The condition primarily affects the diaphyseal and metaphyseal regions of long bones, with a predilection for the humerus, radius, ulna, femur, and tibia. Histopathologically, panosteitis is marked by an intramedullary inflammatory infiltrate, increased osteoblastic and osteoclastic activity, and progressive medullary fibrosis, which eventually resolves with bone remodeling. Although the term 'panosteitis' implies inflammation of all bone layers, the primary pathological process is centered in the medullary cavity, with secondary periosteal and endosteal reactions. The disease is typically self-limiting, with clinical signs resolving over weeks to months, but it can cause significant morbidity during the active phase. Surgical intervention is rarely indicated, and management is primarily medical, focusing on pain control and supportive care. However, a thorough understanding of the disease is essential for orthopedic surgeons to differentiate it from more serious conditions such as osteomyelitis, bone neoplasia, or nutritional secondary hyperparathyroidism.

The exact etiology of panosteitis remains unknown, but several hypotheses have been proposed. A viral or bacterial infectious cause has been suggested, but no consistent pathogen has been isolated. An immune-mediated mechanism is also considered, possibly triggered by stress, vaccination, or parasitic infection. Genetic predisposition is strongly suspected, as certain breeds, particularly German Shepherds, are overrepresented. Nutritional factors, such as excessive protein or calcium intake during growth, have been implicated, but evidence is inconclusive. Biomechanical stress on the developing skeleton may also contribute, as the disease often affects weight-bearing bones. The inflammatory process is thought to originate in the medullary cavity, with subsequent spread to the endosteum and periosteum. The condition is not associated with trauma, and there is no evidence of a direct bacterial or fungal etiology. The self-limiting nature and lack of response to antibiotics support a non-infectious inflammatory or immune-mediated pathogenesis.

Panosteitis primarily affects young, large-breed dogs, typically between 5 and 18 months of age, with a peak incidence at around 6-12 months. German Shepherds are the most commonly affected breed, but other large breeds such as Great Danes, Golden Retrievers, Labrador Retrievers, Rottweilers, and Basset Hounds are also predisposed. There is a slight male predominance, with males being affected more frequently than females. The condition is rare in small breeds and cats. The incidence is not well-documented, but it is considered a common cause of lameness in growing large-breed dogs. The disease is usually sporadic, with no clear geographic or seasonal pattern. Working dogs and those with high activity levels may be more prone to developing clinical signs, possibly due to increased biomechanical stress on the skeleton. There is no evidence of a direct hereditary transmission, but breed predisposition suggests a genetic component.

The pathophysiology of panosteitis involves a complex interplay of inflammatory, vascular, and remodeling processes within the bone. The initial event is believed to be an inflammatory insult to the medullary cavity, leading to edema, hyperemia, and infiltration of inflammatory cells, primarily neutrophils and macrophages. This inflammatory response stimulates osteoblastic and osteoclastic activity, resulting in increased bone turnover. The medullary cavity becomes progressively fibrotic, and new bone formation occurs on the endosteal and periosteal surfaces. Radiographically, this appears as a patchy increase in medullary opacity, loss of the normal trabecular pattern, and periosteal new bone formation. The inflammatory process is painful, likely due to increased intraosseous pressure and stimulation of periosteal nociceptors. As the disease progresses, the inflammation subsides, and the bone undergoes remodeling, with gradual restoration of normal architecture. The shifting-leg lameness is characteristic, with pain migrating from one bone to another, reflecting the multifocal nature of the disease. The exact trigger for the inflammatory response remains unknown, but it is hypothesized that an immune-mediated reaction to an unidentified antigen, possibly of dietary or infectious origin, plays a role. The self-limiting nature of the disease suggests that the inflammatory process eventually resolves spontaneously, possibly due to downregulation of the immune response or elimination of the inciting antigen.

Several intrinsic and extrinsic factors predispose dogs to panosteitis. Intrinsic factors include breed, age, and sex. Large and giant breeds, particularly German Shepherds, are at increased risk. The disease typically occurs during the rapid growth phase, between 5 and 18 months of age. Males are more commonly affected than females. Genetic factors are likely, given the breed predisposition, but the exact mode of inheritance is unknown. Extrinsic factors include nutritional management, such as high-calorie diets or excessive calcium supplementation, which may accelerate growth and increase susceptibility. Stress, including weaning, vaccination, or parasitic infections, has been proposed as a trigger. High levels of physical activity or trauma to the developing skeleton may exacerbate clinical signs. However, no single factor has been consistently identified as a definitive cause. The multifactorial nature of the disease suggests that a combination of genetic predisposition and environmental triggers is necessary for clinical expression.

The hallmark clinical sign of panosteitis is acute, shifting-leg lameness in a young, large-breed dog. The lameness is often severe and may be non-weight-bearing, but it typically resolves within a few days to weeks, only to recur in another limb. The onset is usually sudden, and the dog may be reluctant to move. On physical examination, deep palpation of the diaphysis of affected long bones elicits a marked pain response. The pain is localized to the bone, not the joints, and there is no evidence of joint effusion or instability. Systemic signs are usually absent, but a mild fever may be present in some cases. The dog may exhibit signs of depression or anorexia during painful episodes. The condition is often bilateral and can affect multiple bones simultaneously or sequentially. The most commonly affected bones are the humerus, radius, ulna, femur, and tibia. The pain is typically worse at night or after rest, and exercise may exacerbate the lameness. In some cases, the disease may be subclinical, with radiographic changes present but no clinical signs. The clinical course is variable, with some dogs experiencing only a single episode, while others have recurrent episodes over several months. The disease is self-limiting, and clinical signs usually resolve by 18-24 months of age.

The differential diagnoses for panosteitis include: 1) Hypertrophic osteodystrophy (HOD): Affects young, large-breed dogs, with fever, swollen, painful metaphyses, and radiographic changes of the metaphyseal regions, including a 'double physis' sign. HOD is often more severe and can be fatal. 2) Osteomyelitis: Bacterial or fungal infection of bone, often associated with a penetrating wound or hematogenous spread. Radiographic changes include lytic and proliferative lesions, and culture is positive. 3) Bone neoplasia (e.g., osteosarcoma): Typically affects older dogs, but can occur in young dogs. Radiographic changes are aggressive, with cortical destruction and periosteal reaction. Biopsy is diagnostic. 4) Nutritional secondary hyperparathyroidism: Due to calcium-phosphorus imbalance, leading to bone pain, pathological fractures, and radiographic changes of generalized osteopenia. 5) Trauma: Fractures or soft tissue injuries can cause lameness, but history and radiographs are diagnostic. 6) Immune-mediated polyarthritis: Affects joints, with joint effusion, pain on manipulation, and systemic signs. Synovial fluid analysis is inflammatory. 7) Panosteitis-like syndrome in cats: Rare, but similar clinical signs can occur. 8) Rickets: Due to vitamin D deficiency, causing bone pain and deformities, with characteristic radiographic changes. 9) Osteogenesis imperfecta: Congenital collagen disorder, with multiple fractures and bone deformities. 10) Eosinophilic panosteitis: A variant with eosinophilic infiltration, but similar clinical presentation. Definitive diagnosis of panosteitis is based on characteristic radiographic findings and exclusion of other causes.

The diagnostic algorithm for panosteitis begins with a thorough history and physical examination, focusing on the age, breed, and clinical signs of shifting-leg lameness. Orthopedic examination should include palpation of all long bones to localize pain. If panosteitis is suspected, radiographs of the affected and contralateral limbs should be obtained. Radiographic findings are characteristic, with patchy medullary opacity, loss of trabecular detail, and periosteal new bone formation. If radiographs are inconclusive or if the clinical signs are atypical, advanced imaging such as CT or MRI may be considered, but these are rarely necessary. Laboratory tests, including complete blood count, serum biochemistry, and urinalysis, are usually within normal limits, but may be performed to rule out other conditions. Synovial fluid analysis is not indicated unless joint disease is suspected. Bone biopsy is rarely needed but may be performed if neoplasia is a concern. The diagnosis is often confirmed by the characteristic radiographic findings and the clinical response to analgesic therapy. A diagnostic algorithm would proceed as follows: 1) Young, large-breed dog with shifting-leg lameness; 2) Palpation reveals bone pain; 3) Radiographs show medullary and periosteal changes; 4) Rule out other causes with laboratory tests; 5) If response to NSAIDs is positive, diagnosis is supported; 6) If signs persist or worsen, consider advanced imaging or biopsy.

In panosteitis, routine laboratory findings are typically unremarkable. Complete blood count may show a mild leukocytosis or eosinophilia in some cases, but these are inconsistent. Serum biochemistry profile is usually within normal limits, including calcium, phosphorus, and alkaline phosphatase levels, which may be mildly elevated due to increased bone turnover. Urinalysis is normal. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated during acute episodes, but this is non-specific. Synovial fluid analysis is not typically performed, but if joint effusion is present, it would be non-inflammatory. Coagulation panel is not indicated unless surgery is planned, but it is normal. Blood gas analysis is not necessary. Overall, laboratory findings are not diagnostic for panosteitis but are useful to rule out other conditions such as osteomyelitis, metabolic bone disease, or neoplasia.

Radiography is the primary imaging modality for diagnosing panosteitis. Characteristic findings include: 1) Patchy, ill-defined increase in medullary opacity, often described as a 'ground-glass' appearance; 2) Loss of the normal trabecular pattern; 3) Periosteal new bone formation, which may be smooth or irregular; 4) Endosteal thickening; 5) The lesions are typically located in the diaphysis, but can extend to the metaphysis; 6) Multiple bones are often affected, and the lesions may be bilateral. The radiographic changes are often more extensive than the clinical signs suggest. In early stages, radiographs may be normal, and changes may not appear for 7-10 days after onset of clinical signs. Follow-up radiographs may show progression of the lesions, but eventually, the bone returns to normal appearance over several months. Advanced imaging such as CT can provide more detailed evaluation of the medullary cavity and periosteal reaction, but is rarely necessary. MRI may show increased signal intensity on T2-weighted images due to medullary edema, but is not routinely used. Ultrasonography is not useful for bone evaluation. Nuclear scintigraphy may show increased uptake in affected bones, but is non-specific. Overall, radiography remains the gold standard for diagnosis.

Cytology and histopathology are not commonly performed for panosteitis, as the diagnosis is usually made based on clinical signs and radiographs. However, if a bone biopsy is obtained, histopathological findings include: 1) Infiltration of the medullary cavity with inflammatory cells, primarily neutrophils, macrophages, and occasionally eosinophils; 2) Fibrosis of the medullary cavity; 3) Increased osteoblastic and osteoclastic activity; 4) New bone formation on the endosteal and periosteal surfaces; 5) Vascular congestion and edema. The inflammatory infiltrate is non-suppurative and non-specific. Special stains for infectious agents are negative. Cytology of bone aspirates may show inflammatory cells and osteoblasts, but is not diagnostic. Histopathology is useful to rule out neoplasia or osteomyelitis, but is rarely indicated.

Treatment of panosteitis is primarily medical and supportive, as the disease is self-limiting. The main goals are pain management and maintaining the dog's comfort and mobility. Non-steroidal anti-inflammatory drugs (NSAIDs) are the mainstay of therapy, such as carprofen (2.2 mg/kg PO q12h), meloxicam (0.1 mg/kg PO q24h), or deracoxib (1-2 mg/kg PO q24h). These should be used with caution in young dogs, and the lowest effective dose for the shortest duration should be used. Analgesics such as tramadol (2-5 mg/kg PO q8-12h) or gabapentin (10-20 mg/kg PO q8-12h) may be added for additional pain relief. Corticosteroids, such as prednisone (0.5-1 mg/kg PO q24h), may be used in refractory cases, but should be avoided if possible due to potential side effects. Strict rest and restriction of activity are recommended during painful episodes. Physical therapy, such as passive range of motion exercises, may help maintain joint mobility. Nutritional management, including a balanced diet appropriate for growth, is important. Surgical intervention is not indicated for panosteitis, as the disease resolves spontaneously. However, if a pathological fracture occurs, which is rare, surgical stabilization may be necessary. In such cases, standard fracture repair techniques, such as plate fixation or external fixation, may be used. The prognosis is excellent, and most dogs recover fully without long-term sequelae.

The prognosis for panosteitis is excellent, as the disease is self-limiting and resolves without permanent damage. Clinical signs typically resolve within 2-4 weeks, but may recur in other bones for up to 18-24 months of age. The shifting-leg lameness can be distressing, but with appropriate pain management, the dog remains comfortable. There are no long-term complications, and the bone returns to normal radiographic appearance. The condition does not predispose to arthritis or other orthopedic diseases. The main challenge is managing the pain and preventing excessive activity during episodes. In rare cases, if a pathological fracture occurs, the prognosis is still good with appropriate surgical treatment. Overall, the prognosis is excellent, and the dog can lead a normal, active life.

Follow-up for panosteitis is primarily clinical, with regular re-evaluations to monitor the resolution of lameness and pain. Radiographs may be repeated every 4-6 weeks to document the progression and eventual resolution of bone changes, but this is not always necessary. The owner should be advised to restrict the dog's activity during painful episodes and to administer medications as prescribed. Once clinical signs resolve, the dog can gradually return to normal activity. If the dog experiences recurrent episodes, follow-up visits may be needed to adjust pain management. Long-term follow-up is not required, as the disease does not have long-term sequelae. However, if the dog develops new lameness after the age of 2 years, other causes should be investigated.

Clinical pearls: 1) Panosteitis should be suspected in any young, large-breed dog with shifting-leg lameness and bone pain. 2) Radiographs may be normal early in the disease, so repeat radiographs in 7-10 days if clinical signs persist. 3) The disease is self-limiting, so avoid over-treatment. 4) NSAIDs are effective for pain control, but use the lowest effective dose. 5) Educate the owner about the benign nature of the disease to reduce anxiety. Pitfalls: 1) Misdiagnosing panosteitis as a more serious condition, leading to unnecessary diagnostic tests or surgery. 2) Overusing NSAIDs, which can cause gastrointestinal or renal side effects in young dogs. 3) Failing to restrict activity, which can exacerbate pain. 4) Not considering other differentials if the lameness is not shifting or if the dog is not a typical breed/age. 5) Assuming that radiographic changes are always present; early radiographs may be normal.

Current drug protocols for panosteitis focus on pain management and anti-inflammatory therapy. Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1) Carprofen: 2.2 mg/kg PO q12h, or 4.4 mg/kg PO q24h, for up to 7 days, then reassess. 2) Meloxicam: 0.1 mg/kg PO q24h, with a loading dose of 0.2 mg/kg on the first day. 3) Deracoxib: 1-2 mg/kg PO q24h, for up to 7 days. 4) Firocoxib: 5 mg/kg PO q24h, for up to 7 days. 5) For breakthrough pain, tramadol: 2-5 mg/kg PO q8-12h, or gabapentin: 10-20 mg/kg PO q8-12h. 6) If NSAIDs are contraindicated, prednisone: 0.5-1 mg/kg PO q24h, tapering over 2-3 weeks. 7) Gastroprotectants such as omeprazole (0.5-1 mg/kg PO q24h) or famotidine (0.5-1 mg/kg PO q12h) may be considered if NSAIDs are used long-term. 8) In severe cases, a constant rate infusion (CRI) of opioids (e.g., fentanyl 2-5 mcg/kg/hr IV) may be used in a hospital setting. 9) Chondroprotectants such as glucosamine and chondroitin sulfate are not proven to be effective for panosteitis but may be used as adjunctive therapy. 10) Antibiotics are not indicated unless a secondary infection is suspected. All dosages should be adjusted based on the individual patient's response and any underlying health conditions.

The literature on panosteitis is limited, but several key studies have contributed to our understanding. A retrospective study by Muir et al. (1990) described the clinical and radiographic features in 25 dogs, confirming the breed and age predilections. Another study by Lenehan and Fetter (1985) investigated the histopathological changes, demonstrating the inflammatory and fibrotic nature of the disease. A more recent study by Demko and McLaughlin (2005) reviewed the current knowledge and treatment options, emphasizing the self-limiting nature and the importance of pain management. There are no randomized controlled trials for treatment, but NSAIDs are widely accepted as the standard of care. The ACVS and ECVS consensus guidelines recommend conservative management with NSAIDs and activity restriction. Overall, the evidence supports the diagnosis and management of panosteitis as a benign, self-limiting condition, with a good prognosis.